ExploreWatchlistsPricing
  1. US-listed companies
  2. Theravance Biopharma, Inc.
  3. Financials
  4. Total assets

Theravance Biopharma, Inc. (TBPH)

Market cap
$849.63M
P/E ratio
8x
SummaryFinancials
Period EndTotal assets (Million USD)YoY (%)
Dec 31, 2025486+37.10%
Dec 31, 2024354-7.29%
Dec 31, 2023382-37.11%
Dec 31, 2022607+62.05%
Dec 31, 2021375-20.09%
Dec 31, 2020469+14.73%
Dec 31, 2019409-27.03%
Dec 31, 2018560+26.92%
Dec 31, 2017441-30.95%
Dec 31, 2016639+113.00%
Dec 31, 2015300-11.15%
Dec 31, 2014338

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat